Recruiting Phase 1 2025-524480-21-00

The clinical trial to study a new drug, AP-2.

Phase 1 – testing safety in a small group of people

Conditions: ALS and related disorders like frontotemporal dementia and Alexander disease.

Sponsor: Molefy Pharma S.L.

trial.available_in:

БГ

Overview

Trial status: Authorised

Who can participate

Age group: 18-64 years Gender: Male Target enrollment: 72 participants

Spain (1)

Status

Recruiting

Phase

Phase 1

Study type

INTERVENTIONAL

Sex

Male only

Minimum age

18 Years

Maximum age

64 Years

Healthy volunteers

Start date

10.03.2026

Registry ID

2025-524480-21-00

Source

euclinicaltrials.eu

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.